Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 9,345,750

« Back to Dashboard

Which drugs does patent 9,345,750 protect, and when does it expire?

Patent 9,345,750 protects TOUJEO SOLOSTAR and is included in one NDA.

This patent has forty-nine patent family members in thirty-five countries.

Summary for Patent: 9,345,750

Title:Long-acting formulations of insulin
Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.
Inventor(s): Becker; Reinhard (Frankfurt am Main, DE), Hahn; Annke (Frankfurt am Main, DE), Boderke; Peter (Schwalbach, DE), Fuerst; Christiane (Frankfurt am Main, DE), Mueller; Werner (Frankfurt am Main, DE), Werner; Ulrich (Frankfurt am Main, DE)
Assignee: SANOFI (Paris, FR)
Application Number:14/220,562
Patent Claim Types:
see list of patent claims
Formulation; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Us Services
TOUJEO SOLOSTAR
insulin glargine recombinant
SOLUTION;SUBCUTANEOUS206538-001Feb 25, 2015RXYesYes9,345,750► SubscribeY IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,345,750

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10305532May 19, 2010
10305780Jul 13, 2010
11305140Feb 10, 2011

International Patent Family for Patent: 9,345,750

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina081200► Subscribe
Australia2011202239► Subscribe
Brazil112012029131► Subscribe
Canada2792669► Subscribe
Chile2012003197► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc